117 related articles for article (PubMed ID: 8075054)
1. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).
Wierzbicki R; Ezzat A; Abdel-Warith A; Ayoub A; Kagevi I; Fadda M; Sieck J; Abdulkareem M; Amin T; Yazigi A
Ann Oncol; 1994 May; 5(5):466-7. PubMed ID: 8075054
[No Abstract] [Full Text] [Related]
2. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
[TBL] [Abstract][Full Text] [Related]
3. [The effect and pharmacokinetics of etoposide in patients with primary hepatocellular carcinoma].
Funakoshi S; Aiba K; Dobashi F; Inamoto Y; Hirano A; Tada N; Ogihara A; Fujii T; Kuraishi Y; Yamada T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):165-7. PubMed ID: 8380686
[No Abstract] [Full Text] [Related]
4. Phase II study of oral VP-16-213 in hepatocellular carcinoma.
Cavalli F; Rozencweig M; Renard J; Goldhirsch A; Hansen HH
Eur J Cancer Clin Oncol; 1981 Oct; 17(10):1079-82. PubMed ID: 6279406
[No Abstract] [Full Text] [Related]
5. Long-term survival and complete response to adriamycin and etoposide in a case of hepatocellular carcinoma.
Giaccone G; Bonardi G; Leria G; Donadio M; Calciati A
Tumori; 1986 Aug; 72(4):409-11. PubMed ID: 3020753
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.
Shiu W; Mok SD; Leung N; Li M; Zacharia A; Li A; Martin C
Jpn J Clin Oncol; 1987 Jun; 17(2):113-5. PubMed ID: 3039199
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
8. [Hepatic arterial infusion chemotherapy for hepatocellular carcinoma by EEP regimen].
Takayasu Y
Nihon Rinsho; 2001 Oct; 59 Suppl 6():624-8. PubMed ID: 11762024
[No Abstract] [Full Text] [Related]
9. [Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU].
Tarusawa K; Yodono H; Sasaki T; Ikami I; Fujii N; Akimura R; Nakamura Y; Kanehira J; Midorikawa H; Kimura T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):53-8. PubMed ID: 2153370
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study.
Bobbio-Pallavicini E; Porta C; Moroni M; Bertulezzi G; Civelli L; Pugliese P; Nastasi G
Eur J Cancer; 1997 Oct; 33(11):1784-8. PubMed ID: 9470833
[TBL] [Abstract][Full Text] [Related]
11. Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Lencioni M; Falcone A; Allegrini G; Pfanner E; Masi G; Brunetti I; Di Marsico R; Fontana E; Orlandini C; Stampino CG; Bartolozzi C; Conte PF
Oncology; 2000 Sep; 59(3):204-9. PubMed ID: 11053987
[TBL] [Abstract][Full Text] [Related]
12. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
Casanova M; Massimino M; Ferrari A; Spreafico F; Piva L; Coppa J; Luksch R; Cefalo G; Terenziani M; Polastri D; Bellani FF; Mazzaferro V
Pediatr Hematol Oncol; 2005; 22(3):189-98. PubMed ID: 16020101
[TBL] [Abstract][Full Text] [Related]
13. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Yau T; Chan P; Pang R; Ng K; Fan ST; Poon RT
Cancer; 2010 Nov; 116(21):5022-9. PubMed ID: 20629034
[TBL] [Abstract][Full Text] [Related]
14. [Phase I clinical study of NK 171 (etoposide)].
Kimura K; Yamada K; Niitani H
Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
[TBL] [Abstract][Full Text] [Related]
15. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin.
Melia WM; Johnson PJ; Williams R
Cancer; 1983 Jan; 51(2):206-10. PubMed ID: 6295596
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
17. Oral fluorouracil therapy of hepatoma.
Kennedy PS; Lehane DE; Smith FE; Lane M
Cancer; 1977 May; 39(5):1930-5. PubMed ID: 192440
[TBL] [Abstract][Full Text] [Related]
18. [Intra-arterial infusion chemotherapy for unresectable hepatocellular carcinoma using an implantable reservoir].
Kamiyama T; Une Y; Nakajima Y; Matsuoka S; Nagabuchi E; Gotoda A; Saito M; Uchino J
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1851-5. PubMed ID: 1652225
[TBL] [Abstract][Full Text] [Related]
19. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
Suto T; Yoshida Y; Sakata Y; Ono T; Yoshida T; Yamada N; Chida N; Oohira H
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1933-8. PubMed ID: 9797816
[TBL] [Abstract][Full Text] [Related]
20. [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection].
Matsushita A; Hanazaki K; Noike T; Nakagawa K; Misawa R; Nakata T; Nomura K; Kobayashi A; Miwa S; Miyagawa S; Kawasaki S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1327-32. PubMed ID: 14518415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
